Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Short-term Investments (2020 - 2026)

Ani Pharmaceuticals' Short-term Investments history spans 5 years, with the latest figure at $36000.0 for Q4 2025.

  • On a quarterly basis, Short-term Investments rose 9.09% to $36000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $36000.0, a 9.09% increase, with the full-year FY2025 number at $36000.0, up 9.09% from a year prior.
  • Short-term Investments hit $36000.0 in Q4 2025 for Ani Pharmaceuticals, roughly flat from $36000.0 in the prior quarter.
  • Over the last five years, Short-term Investments for ANIP hit a ceiling of $5.0 million in Q4 2022 and a floor of $33000.0 in Q4 2024.
  • Historically, Short-term Investments has averaged $2.3 million across 4 years, with a median of $36000.0 in 2025.
  • Biggest five-year swings in Short-term Investments: decreased 0.04% in 2021 and later rose 9.09% in 2025.
  • Tracing ANIP's Short-term Investments over 4 years: stood at $5.0 million in 2021, then increased by 0.1% to $5.0 million in 2022, then tumbled by 99.34% to $33000.0 in 2024, then grew by 9.09% to $36000.0 in 2025.
  • Business Quant data shows Short-term Investments for ANIP at $36000.0 in Q4 2025, $36000.0 in Q3 2025, and $36000.0 in Q2 2025.